Till Uhlig

Professor
https://orcid.org/0000-0002-6881-9552

View Google Scholar profile

See publications in PubMed

Education

Dr.med. at the Faculty of Medicine, University of Oslo (2000)
Specialist in Rheumatology (1996)
Doctorate at the Faculty of Medicine, University of Oslo

Position

Senior researcher at the Department of Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital
Senior Consultant at the Department of Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital
Professor II at the Department of Clinical Medicine, University of Oslo

Field of interest

Clinical rheumatology
Gout
Rheumatoid arthritis
Osteoarthritis
Rehabilitation

Other

Leader of work package 6 in REMEDY (Long-term follow-up)

Email

This email address is protected from spambots. You need JavaScript enabled to view it.

Email

+47 22451500

Visiting address

Diakonhjemmet Hospital
Superintendent's residence
Reidar Kobros vei 8
0370 Oslo

Postal address

Diakohjemmet Hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP1 - Optimized medical interventions

ARCTIC

Remission in patients with rheumatoid arthritis: a randomized controlled trial investigating the use of ultrasound in clinical follow-up

EPNOA

Epidemiology of Norwegian Arthritis - A cohort study

WP6 - Dechiphering long-term outcomes

NOR-ECON

Health economics in the treatment of inflammatory arthritic diseases

WP6 - Dechiphering long-term outcomes

NOR-Gout

Gout in Norway

WP1 - Optimized medical interventions

NORTH STAR

The Nordic study of strategy trials and registries for rheumatic diseases

WP3 - Pain mechanisms and management

RehabNytte

Specialized rehabilitation at private rehabilitation institutions

WP6 - Dechiphering long-term outcomes

RehabBenefit - work

Rehabilitation and work participation

WP5 - Innovative approaches to remote care

ReMonit Gout

Gout management app

Publications

Publications retrieved from the National Science Archives (NVA):

Musculoskeletal ultrasound findings in people with asymptomatic hyperuricemia: baseline analysis from the Transitions in Gout Research (TIGER) study using the OMERACT gout ultrasound semiquantitative scoring system

2026

Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial

2026

Duration and dose of allopurinol needed to reach the serum urate target in gout

2026

Hand-dominant joint involvement pattern associates with favorable, and polyarthritis with unfavorable, treatment response to both csDMARDs and bDMARDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trials

2026

Flare risk after oral glucocorticoid bridging with methotrexate or intra-articular bridging with triple therapy in early rheumatoid arthritis

2026

Exploring differences in health-related benefit status in the year before, during and after specialist rehabilitation: a Norwegian case-control study

2026

Remission in gout is possible: 5-year follow-up in the NOR-Gout study

2025

Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls

2025

Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm

2025

Transitional and CD21⁻ PD-1⁺ B cells are associated with remission in early rheumatoid arthritis

2025

Epitopes targeted by autoantibodies in presymptomatic individuals predict early rheumatoid arthritis

2025

Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: Data from a randomized controlled trial

2025

Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial

2025

Acylcarnitine enrichment as a characteristic of rheumatoid arthritis fibroblast-like synoviocyte metabolic fingerprint

2025

Health-related Quality of Life in DMARD-treated adults with Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population

2025

Perceptions about asymptomatic hyperuricemia and views about urate‐lowering therapy in people with asymptomatic hyperuricemia

2025

Association of Soluble Immune Checkpoint Molecules PD1 and 4‐1BB With CTLA‐4Ig Treatment Response in Early Rheumatoid Arthritis

2025

Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis

2025

Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort

2025

Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study

2025

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomized controlled, non-inferiority trial

2024

Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis

2024

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

2024

Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study

2024

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomized controlled trial

2024

Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials

2024

Interstitial lung disease in rheumatoid or psoriatic arthritis patients initiating biologics, and controls - data from five Nordic registries

2024

Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes - results from the NOR-Gout study

2024

Circulating Baseline CXCR3⁺Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis

2024

A genome-wide association analysis reveals new pathogenic pathways in gout*

2024

Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis

2024

Development of gout in people with asymptomatic hyperuricemia: study protocol for a 5-year prospective cohort

2024

Impaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study

2024

Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial

2023

2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases

2023

Work Ability in the Year after Rehabilitation—Results from the RehabNytte Cohort

2023

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study

2023

Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study

2023

Effect of tapered versus stable treatment with tumor necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

2023

EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis

2023

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomized controlled NORD-STAR trial

2023

Beliefs about medicines in gout patients: results from the NOR-Gout 2-year study

2023

Changes in Tophus Composition During Urate-Lowering Therapy: A Dual-Energy Computed Tomography Study

2023

Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout

2022

Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study

2022

Sarcoidosis with musculoskeletal manifestations: systematic review of non-pharmacological and pharmacological treatments

2022

Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomized controlled trial

2022

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study

2022

One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study

2022

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study

2022

Two-year reduction of dual-energy CT urate deposits during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.

2021

Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis

2021

Associations between Fluorescence Optical Imaging and Magnetic Resonance Imaging and symptoms in hand osteoarthritis.

2021

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.

2021

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

2021

Associations between joint pathologies and central sensitization in persons with hand osteoarthritis: Results from the Nor-Hand study

2021

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumor necrosis factor inhibitors: data from register linkage of the NOR-DMARD study

2021

Flare rate thresholds for patient assessment of disease activity states in Gout

2021

Which factors predict discordance between a patient and physician on a gout flare?

2021

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: Achievements of the urate target levels and predictors of obtaining this target

2021

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial

2021

Evaluation of three scoring methods for Fluorescence Optical Imaging in erosive hand osteoarthritis and rheumatoid arthritis

2020

Validity and diagnostic performance of fluorescence optical imaging measuring synovitis in hand osteoarthritis: baseline results from the Nor-Hand cohort

2020

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial

2020

Conventional versus ultrasound treat to target: No difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis

2020

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy

2020

EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyzes of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries

2020

Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study

2020

Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis

2020

Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-to-Target Strategies

2020

Associations Between Radiographic and Ultrasound‐Detected Features in Hand Osteoarthritis and Local Pressure Pain Thresholds

2020

Gout, Hyperuricemia, and Crystal-Associated Disease Network consensus statement regarding labels and definitions for disease elements in gout

2019

2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout

2019

Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries.

2019

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

2019

Trends in All-Cause and Cardiovascular Mortality in Patients With Incident Rheumatoid Arthritis: A 20-year Follow-Up Matched Case-Cohort Study

2019

What Do We Measure With 28-joint DAS in Elderly Patients? An Exploratory Analysis in the NOR-DMARD Study

2019

Swollen, but not tender joints, are independently associated with ultrasound synovitis: Results from a longitudinal observational study of patients with established rheumatoid arthritis

2019

Peripheral and Central Sensitization of Pain in Individuals With Hand Osteoarthritis and Associations With Self-Reported Pain Severity

2019

Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register

2019

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial

2018

Tender joint count may not reflect inflammatory activity in established rheumatoid arthritis patients: results from a longitudinal study

2018

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study

2018

Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol

2018

Burden of gout in the Nordic region, 1990–2015: findings from the Global Burden of Disease Study 2015

2018

The impact of ultrasound on the use and efficacy of intraarticular glucocorticoid injections in early rheumatoid arthritis: Secondary analyzes from a randomized trial examining the benefit of ultrasound in a clinical tight control regimen

2018

Treating fatigue in rheumatoid arthritis: does patient age matter?

2018

Health‐related quality of life in women with endometriosis, compared with the general population and women with rheumatoid arthritis

2018

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes

2018

Health-related quality of life in patients with psoriatic and rheumatoid arthritis: Data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls

2018

The eumusc.net standards of care for rheumatoid arthritis: Importance and current implementation according to patients and healthcare providers in the Netherlands

2018

Pain catastrophizing is strongly associated with subjective outcomes, but not with inflammatory assessments in rheumatoid arthritis patients.

2018

Deriving common comorbidity indices from the MedDRA classification and exploring their performance on key outcomes in patients with rheumatoid arthritis

2018

Developing and testing a consensus-based core set of outcome measures for rehabilitation in musculoskeletal diseases

2018

Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons

2017

Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: Study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study

2017

Exercise for Hand Osteoarthritis: A Cochrane Systematic Review

2017

Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard

2017

Exercise for hand osteoarthritis

2017

Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria

2017

Sleep disturbance in patients with rheumatoid arthritis is related to fatigue, disease activity, and other patient-reported outcomes

2017

Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register

2017

Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists

2016

Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard

2016

2016 updated EULAR evidence-based recommendations for the management of gout

2016

Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD

2016

Gout - new in diagnostics and treatment

2016

Ultrasound in the management of rheumatoid arthritis: ARCTIC randomized controlled strategy trial

2016

Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach

2016

Predictive value of arterial stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with rheumatoid arthritis

2016

Achievement of remission and low disease activity definitions in patients with rheumatoid arthritis in clinical practice: Results from the Nor-Dmard study

2016

Till Uhlig

Education

Position

Field of interest

Other

Email

Email

Visiting address

Postal address

Projects

Publications

Publications retrieved from the National Science Archives (NVA):

Musculoskeletal ultrasound findings in people with asymptomatic hyperuricemia: baseline analysis from the Transitions in Gout Research (TIGER) study using the OMERACT gout ultrasound semiquantitative scoring system

Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial

Duration and dose of allopurinol needed to reach the serum urate target in gout

Hand-dominant joint involvement pattern associates with favorable, and polyarthritis with unfavorable, treatment response to both csDMARDs and bDMARDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trials

Flare risk after oral glucocorticoid bridging with methotrexate or intra-articular bridging with triple therapy in early rheumatoid arthritis

Exploring differences in health-related benefit status in the year before, during and after specialist rehabilitation: a Norwegian case-control study

Remission in gout is possible: 5-year follow-up in the NOR-Gout study

Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls

Transitional and CD21− PD-1+ B cells are associated with remission in early rheumatoid arthritis

Epitopes targeted by autoantibodies in presymptomatic individuals predict early rheumatoid arthritis

Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: Data from a randomized controlled trial

Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial

Acylcarnitine enrichment as a characteristic of rheumatoid arthritis fibroblast-like synoviocyte metabolic fingerprint

Health-related Quality of Life in DMARD-treated adults with Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population

Perceptions about asymptomatic hyperuricemia and views about urate‐lowering therapy in people with asymptomatic hyperuricemia

Association of Soluble Immune Checkpoint Molecules PD1 and 4‐1BB With CTLA‐4Ig Treatment Response in Early Rheumatoid Arthritis

Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis

Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort

Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomized controlled, non-inferiority trial

Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomized controlled trial

Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials

Interstitial lung disease in rheumatoid or psoriatic arthritis patients initiating biologics, and controls - data from five Nordic registries

Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes - results from the NOR-Gout study

Circulating Baseline CXCR3+Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis

A genome-wide association analysis reveals new pathogenic pathways in gout*

Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis

Development of gout in people with asymptomatic hyperuricemia: study protocol for a 5-year prospective cohort

Impaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study

Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial

2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases

Work Ability in the Year after Rehabilitation—Results from the RehabNytte Cohort

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study

Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study

Effect of tapered versus stable treatment with tumor necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomized controlled NORD-STAR trial

Beliefs about medicines in gout patients: results from the NOR-Gout 2-year study

Changes in Tophus Composition During Urate-Lowering Therapy: A Dual-Energy Computed Tomography Study

Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout

Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study

Sarcoidosis with musculoskeletal manifestations: systematic review of non-pharmacological and pharmacological treatments

Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomized controlled trial

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study

One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study

Two-year reduction of dual-energy CT urate deposits during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.

Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis

Associations between Fluorescence Optical Imaging and Magnetic Resonance Imaging and symptoms in hand osteoarthritis.

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

Associations between joint pathologies and central sensitization in persons with hand osteoarthritis: Results from the Nor-Hand study

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumor necrosis factor inhibitors: data from register linkage of the NOR-DMARD study

Flare rate thresholds for patient assessment of disease activity states in Gout

Which factors predict discordance between a patient and physician on a gout flare?

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: Achievements of the urate target levels and predictors of obtaining this target

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial

Evaluation of three scoring methods for Fluorescence Optical Imaging in erosive hand osteoarthritis and rheumatoid arthritis

Validity and diagnostic performance of fluorescence optical imaging measuring synovitis in hand osteoarthritis: baseline results from the Nor-Hand cohort

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial

Conventional versus ultrasound treat to target: No difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy

EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyzes of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries

Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study

Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis

Transitional and CD21⁻ PD-1⁺ B cells are associated with remission in early rheumatoid arthritis

Circulating Baseline CXCR3⁺Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis